StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) stock

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11+0.00 (0.00%)

Close on Nov 18, 2026Market cap $231.62MP/E –Yield –

Rocket Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Rocket Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $124.37M, down 21.4% year over year. For fiscal 2025 it was $142.02M, down 17.1% from the year before. Over ten years it grew 27.5% a year on average. The highest annual figure on record is $186.34M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$142.02M-17.1%
FY2024Dec 31, 2024$171.24M-8.1%
FY2023Dec 31, 2023$186.34M+12.5%
FY2022Dec 31, 2022$165.57M+32.0%
FY2021Dec 31, 2021$125.48M+19.0%
FY2020Dec 31, 2020$105.44M+82.1%
FY2019Dec 31, 2019$57.91M+8.7%
FY2018Dec 31, 2018$53.27M+257.1%
FY2017Dec 31, 2017$14.92M+148.9%
FY2016Dec 31, 2016$5.99M-52.3%
FY2015Dec 31, 2015$12.55M+124.5%
FY2014Dec 31, 2014$5.59M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$29.50M-30.9%
Q1 FY2026Mar 31, 2026$31.45M-12.5%
Q4 FY2025Dec 31, 2025$29.35M-21.4%
Q3 FY2025Sep 30, 2025$34.07M-19.5%
Q2 FY2025Jun 30, 2025$42.66M-8.0%
Q1 FY2025Mar 31, 2025$35.94M-20.5%
Q4 FY2024Dec 31, 2024$37.36M-10.5%
Q3 FY2024Sep 30, 2024$42.32M-9.7%
Q2 FY2024Jun 30, 2024$46.35M-9.8%
Q1 FY2024Mar 31, 2024$45.23M-2.5%
Q4 FY2023Dec 31, 2023$41.74M-16.6%
Q3 FY2023Sep 30, 2023$46.84M+8.0%
Q2 FY2023Jun 30, 2023$51.38M+24.2%
Q1 FY2023Mar 31, 2023$46.37M+50.6%
Q4 FY2022Dec 31, 2022$50.04M+51.5%
Q3 FY2022Sep 30, 2022$43.38M+9.5%
Q2 FY2022Jun 30, 2022$41.36M+68.6%
Q1 FY2022Mar 31, 2022$30.79M+8.8%
Q4 FY2021Dec 31, 2021$33.02M-34.1%
Q3 FY2021Sep 30, 2021$39.62M+82.9%
Q2 FY2021Jun 30, 2021$24.53M+46.6%
Q1 FY2021Mar 31, 2021$28.31M+66.9%
Q4 FY2020Dec 31, 2020$50.09M+259.0%
Q3 FY2020Sep 30, 2020$21.66M+46.0%
Q2 FY2020Jun 30, 2020$16.73M+19.6%
Q1 FY2020Mar 31, 2020$16.96M+12.0%
Q4 FY2019Dec 31, 2019$13.95M-41.1%
Q3 FY2019Sep 30, 2019$14.83M+13.5%
Q2 FY2019Jun 30, 2019$13.99M+29.9%
Q1 FY2019Mar 31, 2019$15.14M+163.6%
Q4 FY2018Dec 31, 2018$23.68M+381.5%
Q3 FY2018Sep 30, 2018$13.07M+167.0%
Q2 FY2018Jun 30, 2018$10.77M+282.1%
Q1 FY2018Mar 31, 2018$5.74M+151.3%
Q4 FY2017Dec 31, 2017$4.92M-48.2%
Q3 FY2017Sep 30, 2017$4.89M-41.8%
Q2 FY2017Jun 30, 2017$2.82M–
Q1 FY2017Mar 31, 2017$2.29M–
Q4 FY2016Dec 31, 2016$9.49M–
Q3 FY2016Sep 30, 2016$8.41M–

More Rocket Pharmaceuticals figures

See a number that looks wrong?